Open AccessIn vitro activity of BMY-28142 in comparison with those of other beta-lactam antimicrobial agents
Author(s) -
A Tsuji,
Antonios N. Maniatis,
Miriam Bertram,
Leonie S. Young
Publication year - 1985
Publication title -
antimicrobial agents and chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.07
H-Index - 259
eISSN - 1070-6283
pISSN - 0066-4804
DOI - 10.1128/aac.27.4.515
Subject(s) - ceftazidime , cefoperazone , cephalosporin , cefotaxime , microbiology and biotechnology , moxalactam , cephem , broth microdilution , antimicrobial , minimum inhibitory concentration , ceftriaxone , agar dilution , klebsiella , enterobacter , proteus , serratia , biology , pseudomonas aeruginosa , antibiotics , escherichia coli , imipenem , pseudomonas , bacteria , antibiotic resistance , biochemistry , carboxylic acid , genetics , gene
The in vitro susceptibility of 406 clinical isolates to BMY-28142, a new semisynthetic cephem, was evaluated and compared with cefpimizole, HR 810, ceftazidime, cefotaxime, moxalactam, and cefoperazone in a broth microdilution assay. On a weight basis, the activity of BMY-28142 against Escherichia coli, Proteus species, and Klebsiella-Enterobacter-Serratia was superior to the other cephems. Against gentamicin-susceptible and -resistant Pseudomonas aeruginosa, BMY-28142 was more active than the other cephems, except ceftazidime and HR 810. A total of 74% of gram-negative and 56% of gram-positive isolates resistant to third-generation cephalosporins were susceptible to less than or equal to 8 micrograms of BMY-28142 per ml. Finally, for 83% of tested isolates, the bactericidal concentration of BMY-28142 was within one dilution of the inhibitory concentration.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom